A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03755518 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Slow accrual.

Conditions

Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG: FEDRATINIB

Sponsor

Celgene

Collaborators

[object Object]